Metabolic targeting of cancers: From molecular mechanisms to therapeutic strategies

Current Medicinal Chemistry

Volumn 16, Issue 13, 2009, Pages 1561-1587

  Sheng, Huaming ^a   Niu, Ben ^a   Sun, Hongbin ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Fatty acid; Glucose; Glutamine; Metabolic interference; Oncogenic signals; Tumor energy metabolism

Indexed keywords

2,5 ANHYDRO DEXTRO MANNITOL; 3 (3 PYRIDINYL) 1 (4 PYRIDINYL) 2 PROPEN 1 ONE; 6 PHOSPHOFRUCTOKINASE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BROMOPYRUVIC ACID; CHLORAMBUCIL; DEOXYGLUCOSE; DICHLOROACETIC ACID; FATTY ACID SYNTHASE INHIBITOR; FLAVONOL; GLUCOSE TRANSPORTER; GLUFOSFAMIDE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GLYCOGEN SYNTHASE KINASE 3BETA; GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR; GOSSYPOL; HEXOKINASE INHIBITOR; IODOACETIC ACID; LACTATE DEHYDROGENASE; LACTATE DEHYDROGENASE INHIBITOR; LONIDAMINE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PLATINUM COMPLEX; PROTEIN KINASE B INHIBITOR; PYRUVATE DEHYDROGENASE; PYRUVATE DEHYDROGENASE INHIBITOR; SODIUM GLUCOSE COTRANSPORTER; UNCLASSIFIED DRUG; UNINDEXED DRUG; FATTY ACID; GLUCOSE;

AMINO ACID METABOLISM; ANTINEOPLASTIC ACTIVITY; ANXIETY DISORDER; APOPTOSIS; BRAIN CANCER; BREAST CANCER; CELL METABOLISM; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMPETITIVE INHIBITION; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENERGY METABOLISM; ENZYME INHIBITION; FATTY ACID METABOLISM; GENE EXPRESSION; GLIOBLASTOMA; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLUTAMINE METABOLISM; GLYCOLYSIS; HEAD CANCER; HUMAN; IC 50; KETOGENIC DIET; NECK CANCER; NONHODGKIN LYMPHOMA; NONHUMAN; PANCREAS CANCER; PANCREAS CARCINOMA; PERIPHERAL NERVE TOXICITY; PERIPHERAL NEUROPATHY; PROSTATE CANCER; REVIEW; SEDATION; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; TISSUE DISTRIBUTION; TUMOR CELL; TUMOR CELL DESTRUCTION; UNSPECIFIED SIDE EFFECT; METABOLISM; NEOPLASM;

ENERGY METABOLISM; FATTY ACIDS; GLUCOSE; GLYCOLYSIS; HUMANS; NEOPLASMS;

EID: 67650254751     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709788186255     Document Type: Review

References (221)

1. DeBerardinis, R.J.; Lum, J.J.; Hatzivassiliou, G.; Thompson, C.B. The biology of cancer:mEtabolic reprogramming fuels cell growth and proliferation. Cell. Metab., 2008, 7, 11-20.
2. Garber, K. Energy deregulation: Licensing tumors to grow. Science, 2006, 312, 1158-1159.
3. Hsu, P.P.; Sabatini, D.M. Cancer cell metabolism: Warburg and beyond. Cell, 2008, 134, 703-707.
4. Pelicano, H.; Martin, D.S.; Xu, R.H.; Huang, P. Glycolysis inhibition for anticancer treatment. Oncogene, 2006, 25, 4633-4646.
5. Gatenby, R.A.; Gillies, R.J. Glycolysis in cancer: A potential target for therapy. Int. J. Biochem. Cell Biol., 2007, 39, 1358-1366.
6. Vizán, P.; Mazurek, S.; Cascante, M. Robust metabolic adaptation underlying tumor progression. Metabolomics, 2008, 4, 1-12.
7. Menendez, J.A.; Lupu, R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat. Rev. Cancer, 2007, 7, 763-777.
8. Hursting, S.D.; Lashinger, L.M.; Colbert, L.H.; Rogers, C.J.; Wheatley, K.W.; Nunez, N.P.; Mahabir, S.; Barrett, J.C.; Forman, M.R.; Perkins, S.N. Energy balance and carcinogenesis: Underlying pathways and targets for intervention. Curr. Cancer Drug Targets, 2007, 7, 484-491.
9. Merida, I.; Avila-Flores, A. Tumor metabolism: New opportunities for cancer therapy. Clin. Transl. Oncol., 2006, 8, 711-716.
10. Moreno-Sanchez, R.; Rodriguez-Enriquez, S.; Marin-Hernandez, A.; Saavedra, E. FEBS J., 2007, 274, 1393.
11. Deberardinis, R.J.; Sayed, N.; Ditsworth, D.; Thompson, C.B. Brick by brick: Metabolism and tumor cell growth. Curr. Opin. Genet. Dev., 2008, 18, 54-61.
12. Yuneva, M. Finding an "Achilles' heel" of cancer: The role of glucose and glutamine metabolism in the survival of transformed cells. Cell Cycle, 2008, 7, 2083-2089.
13. Jones, R.G.; Plas, D.R.; Kubek, S.; Buzzai, M.; Mu, J.; Xu, Y.; Birnbaum, M.J.; Thompson, C.B. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol. Cell, 2005, 18, 283.
14. Inoki, K.; Zhu, T.; Guan, K.L. TSC2 mediates cellular energy response to control cell growth and survival Cell. 2003, 115, 577-590.
15. Xu, R.H.; Pelicano, H.; Zhou, Y.; Carew, J.S.; Feng, L.; Bhalla, K.N.; Keating, M.J.; Huang, P. Inhibition of glycolysis in cancer cells: A novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res., 2005, 65, 613-621.
16. Nebeling, L.C.; Miraldi, F.; Shurin, S.B.; Lerner, E. Effects of a ketogenic diet on tumor metabolism and nutritional status in pediatric oncology patients: Two case reports. J. Am. Coll. Nutr., 1995, 14, 202-208.
17. Stafstrom, C.E.; Bough, K.J. The ketogenic diet for the treatment of epilepsy: A challenge for nutritional neuroscientists. Nutr. Neurosci., 2003, 6, 67-79.
18. http://www.time.com/time/health/article/0,8599,1662484,00.html (The date of visit: March 8, 2009).
19. Drogat, B.; Bouchecareilh, M.; North, S.; Petibois, C.; Deleris, G.; Chevet, E.; Bikfalvi, A.; Moenner, M. Acute L-glutamine deprivation compromises VEGF-A upregulation in A549/8 human carcinoma cells. J. Cell Physiol., 2007, 212, 463-472.
20. Ellison Bradley, S.; Zanin Mary, K.; Boackle Robert, J. Complement susceptibility in glutamine deprived breast cancer cells. Cell Div., 2007, 2, 20.
21. Larson, S.D.; Li, J.; Chung, D.H.; Evers, B.M. Molecular mechanisms contributing to glutamine-mediated intestinal cell survival. Am. J. Physiol., 2007, 293, G1262-G1271.
22. Paquette, J.C.; Guerin, P.J.; Gauthier, E.R. Rapid induction of the intrinsic apoptotic pathway by L-glutamine starvation. J. Cell. Physiol., 2004, 202, 912-921.
23. Mates, J.M.; Segura, J.A.; Alonso, F. J.; Marquez, J. Pathways from glutamine to apoptosis. Front. Biosci., 2006, 11, 3164-3180.
24. Zhang, X.D.; Deslandes, E.; Villedieu, M.; Poulain, L.; Duval, M.; Gauduchon, P.; Schwartz, L.; Icard, P. Effect of 2-deoxy-D-glucose on various malignant cell lines in vitro. Anticancer Res., 2006, 26, 3561-3566.
25. Maschek, G.; Savaraj, N.; Priebe, W.; Braunschweiger, P.; Hamilton, K.; Tidmarsh, G.F.; De Young, L.R.; Lampidis, T.J. 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res., 2004, 64, 31-34.
26. Lampidis, T., Priebe, W. PCT WO0182926.
27. Postema, M.H.D.; Piper, J.L.; Betts, R.L.; Valeriote, F.A.; Pietraszkewicz, H. RCM-based synthesis of a variety of β-C-glycosides and their in vitro anti-solid tumor activity. J. Org. Chem., 2005, 70, 829-836.
28. Sanhueza, C.A.; Mayato, C.; Garcia-Chicano, M.; Diaz-Penate, R.; Dorta, R.L.; Vazquez, J.T. Antiproliferation and apoptosis induced by C-glycosides in human leukemia cancer cells. Bioorg. Med. Chem. Lett., 2006, 16, 4223-4227.
29. Hersovici, J.; Idriss Bennani-Baiti, M.; Montserret, R.; Frayssinet, C.; Antonakis, K. Design, synthesis and cytotoxic evaluation of keto-C-glycoside fatty acid conjugates. Bioorg. Med. Chem. Lett., 1991, 1, 721-724.
30. http://www.thresholdpharm.com/sec/glufosfamide (The date of visit: March 8, 2009).
31. Seker, H.; Bertram, B.; Burkle, A.; Kaina, B.; Pohl, J.; Koepsell, H.; Wiessler, M. Mechanistic aspects of the cytotoxic activity of glufosfamide, a new tumour therapeutic agent. Br. J. Cancer, 2000, 82, 629-634.
32. Ammons, W.S.; Wang, J.W.; Yang, Z.; Tidmarsh, G.F.; Hoffman, R.M. A novel alkylating agent, glufosfamide, enhances the activity of gemcitabine in vitro and in vivo. Neoplasia, 2007, 9, 625-633.
33. Lindhorst, T.K.; Albertina, C. Essentials of Carbohydrate Chemistry and Biochemistry, Wiley, Chichester, 2003, p. 250.
34. Osborn, H.M.I. Carbohydrates, Elsevier Science, Oxford, 2003, p. 430.
35. Wong, C.H. Carbohydrate-Based Drug Discovery, Wiley-VCH, Weinheim, 2003, p. 1406.
36. Berger, I.; Nazarov, A.A.; Hartinger, C.G.; Groessl, M.; Valiahdi, S.M.; Jakupec, M.A.; Keppler, B.K. A glucose derivative as natural alternative to the cyclohexane-1,2-diamine ligand in the anticancer drug oxaliplatin?. ChemMedChem, 2007, 2, 505-514.
37. Reux, B.; Weber, V.; Galmier, M.J.; Borel, M.; Madesclaire, M.; Madelmont, J.C.; Debiton, E.; Coudert, P. Synthesis and cytotoxic properties of new fluorodeoxyglucose-coupled chlorambucil derivatives. Bioorg. Med. Chem., 2008, 16, 5004-5020.
38. Macheda, M.L.; Rogers, S.; Best, J.D. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J. Cell Physiol., 2005, 202, 654-662.
39. Medina, R.A.; Owen, G.I. Glucose transporters: Expression, regulation and cancer. Biol. Res., 2002, 35, 9-26.
40. Wood, I.S.; Trayhurn, P. Glucose transporters (GLUT and SGLT): Expanded families of sugar transport proteins. Br. J. Nutr., 2003, 89, 3-9.
41. Kashiwaya, Y.; Sato, K.; Tsuchiya, N.; Thomas, S.; Fell, D.A.; Veech, R. L.; Passonneau, J.V. Control of glucose utilization in working perfused rat heart. J. Biol. Chem., 1994, 269, 25502-25514.
42. Rapoport, T.A.; Heinrich, R.; Rapoport, S.M. The regulatory principles of glycolysis in erythrocytes in vivo and in vitro. A minimal comprehensive model describing steady states, quasi-steady states and time-dependent processes. Biochem. J., 1976, 154, 449-469.
43. Torres, N.V.; Mateo, F.; Melendez-Hevia, E.; Kacser, H. Kinetics of metabolic pathways. A system in vitro to study the control of flux. Biochem. J., 1986, 234, 169-174.
44. Godoy, A.; Ulloa, V.; Rodriguez, F.; Reinicke, K.; Yanez, A. J.; Garcia Mde, L.; Medina, R. A.; Carrasco, M.; Barberis, S.; Castro, T.; Martinez, F.; Koch, X.; Vera, J. C.; Poblete, M. T.; Figueroa, C. D.; Peruzzo, B.; Perez, F.; Nualart, F. Differential subcellular distribution of glucose transporters GLUT1-6 and GLUT9 in human cancer: ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues. J. Cell Physiol., 2006, 207, 614-627.
45. Rastogi, S.; Banerjee, S.; Chellappan, S.; Simon, G.R. Glut-1 antibodies induce growth arrest and apoptosis in human cancer cell lines. Cancer Lett., 2007, 257, 244-251.
46. Chan, J.Y.; Kong, S.K.; Choy, Y.M.; Lee, C.Y.; Fung, K.P. Inhibition of glucose transporter gene expression by antisense nucleic acids in HL-60 leukemia cells. Life Sci., 1999, 65, 63-70.
47. Chan, K.K.; Chan, J.Y.; Chung, K.K.; Fung, K.P. Inhibition of cell proliferation in human breast tumor cells by antisense oligonucleotides against facilitative glucose transporter 5. J. Cell Biochem., 2004, 93, 1134-1142.
48. Chen, C.P.; Li, X.X.; Zhang, L.R.; Min, J.M.; Chan, J.Y.W.; Fung, K.P.; Wang, S.Q.; Zhang, L.H. Synthesis of antisense oligonucleotide-peptide conjugate targeting to GLUT-1 in HepG-2 and MCF-7 cells. Bioconjugate Chem., 2002, 13, 525-529.
49. Lee, G.Y.; Kim, S.K.; Byun, Y. Glucosylated heparin derivatives as non-toxic anti-cancer drugs. J. Controlled Release, 2007, 123, 46-55.
50. Halmos, T.; Santarromana, M.; Antonakis, K.; Scherman, D. Synthesis of glucose-chlorambucil derivatives and their recognition by the human GLUT1 glucose transporter. Eur. J. Pharmacol., 1996, 318, 477-484.
51. Prenen, H.; Stefan, C.; Landuyt, B.; Vermaelen, P.; Debiec-Rychter, M.; Bollen, M.; Stroobants, S.; de Bruijn, E.; Mortelmans, L.; Sciot, R.; Schoffski, P.; van Oosterom, A. Imatinib mesylate inhibits glucose uptake in Gastrointestinal Stromal Tumor cells by downregulation of the glucose transporters recruitment to the plasma membrane. Am. J. Biochem. Biotechnol., 2005, 1, 95-102.
52. Kwon, O.; Eck, P.; Chen, S.; Corpe, C.P.; Lee, J.H.; Kruhlak, M.; Levine, M. Inhibition of the intestinal glucose transporter GLUT2 by flavonoids. FASEB J, 2007, 21, 366-377.
53. Harmon, A.W.; Patel, Y.M. Naringenin inhibits glucose uptake in MCF-7 breast cancer cells: A mechanism for impaired cellular proliferation. Breast Cancer Res. Treat., 2004, 85, 103-110.
54. Tatibouet, A.; Yang, J.; Morin, C.; Holman, G.D. Synthesis and evaluation of fructose analogues as inhibitors of the D-fructose transporter GLUT5. Bioorg. Med. Chem., 2000, 8, 1825-1833.
55. Girniene, J.; Tatibouet, A.; Sackus, A.; Yang, J.; Holman, G.D.; Rollin, P. Inhibition of the D-fructose transporter protein GLUT5 by fused-ring glyco-1,3-oxazolidin-2-thiones and -oxazolidin-2-ones. Carbohydr. Res., 2003, 338, 711-719.
56. Asano, T.; Ogihara, T.; Katagiri, H.; Sakoda, H.; Ono, H.; Fujishiro, M.; Anai, M.; Kurihara, H.; Uchijima, Y. Glucose transporter and Na+/ glucose cotransporter as molecular targets of antidiabetic drugs. Curr. Med. Chem., 2004, 11, 2717-2724.
57. Asano, T.; Anai, M.; Sakoda, H.; Fujishiro, M.; Ono, H.; Kurihara, H.; Uchijima, Y. SGLT as a therapeutic target. Drugs Future, 2004, 29, 461-466.
58. Casneuf, V.F.; Fonteyne, P.; Van Damme, N.; Demetter, P.; Pauwels, P.; de Hemptinne, B.; De Vos, M.; Van de Wiele, C.; Peeters, M. Expression of SGLT1, Bcl-2 and p53 in primary pancreatic cancer related to survival. Cancer Invest., 2008, 26, 852-859.
59. Weihua, Z.; Tsan, R.; Huang, W.C.; Wu, Q.; Chiu, C.H.; Fidler, I.J.; Hung, M.C. Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell, 2008, 13, 385-393.
60. Garcea, G.; Manson, M.M.; Neal, C.P.; Pattenden, C.J.; Sutton, C.D.; Dennison, A.R.; Berry, D.P. Glycogen synthase kinase-3 beta; a new target in pancreatic cancer?. Curr. Cancer Drug Targets, 2007, 7, 209-215.
61. Li, D. GSK-3beta as a driving force in ovarian cancer. Cell Res., 2006, 16, 609.
62. Martinez, A.; Castro, A.; Dorronsoro, I.; Alonso, M. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med. Res. Rev., 2002, 22, 373-384.
63. Chen, G.; Huang, L.D.; Jiang, Y.M.; Manji, H.K. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J. Neurochem., 1999, 72, 1327-1330.
64. Meijer, L.; Thunnissen, A.M.; White, A.W.; Garnier, M.; Nikolic, M.; Tsai, L.H.; Walter, J.; Cleverley, K.E.; Salinas, P.C.; Wu, Y.Z.; Biernat, J.; Mandelkow, E.M.; Kim, S.H.; Pettit, G.R. Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent. Chem. Biol. 2000, 7, 51-63
65. Lahusen, T.; de Siervi, A.; Kunick, C.; Senderowica, A.M. Alsterpaullone, a novel cyclin-dependent kinase inhibitor, induces apoptosis by activation of caspase-9 due to perturbation in mitochondrial membrane potential. Mol. Carcinog., 2003, 36, 183-194.
66. Gatenby, R.A.; Gillies, R.J. Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer, 2004, 4, 891-899
67. Kim, J.W.; Dang, C.V. Multifaceted roles of glycolytic enzymes. Trends Biochem. Sci., 2005, 30, 142-150.
68. Kondoh, H.; Lleonart, M.E.; Gil, J.; Wang, J.; Degan, P.; Peters, G.; Martinez, D.; Carnero, A.; Beach, D. Glycolytic enzymes can modulate cellular life span. Cancer Res., 2005, 65, 177-185.
69. Shaw, R.J. Glucose metabolism and cancer. Curr. Opin. Cell Biol., 2006, 18, 598-608.
70. Scatena, R.; Bottoni, P.; Pontoglio, A.; Mastrototaro, L.; Giardina, B. Glycolytic enzyme inhibitors in cancer treatment. Expert Opin. Investig. Drugs, 2008, 17, 1533-1545.
71. Robey, R.B.; Hay, N. Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt. Oncogene, 2006, 25, 4683-4696.
72. Le Goffe, C.; Vallette, G.; Charrier, L.; Candelon, T.; Bou-Hanna, C.; Bouhours, J.F.; Laboisse, C.L. Metabolic control of resistance of human epithelial cells to H2O2 and NO stresses. Biochem. J., 2002, 364, 349-359.
73. Kang, H.T.; Hwang, E.S. 2-Deoxyglucose: An anticancer and antiviral therapeutic, but not any more a low glucose mimetic. Life Sci., 2006, 78, 1392-1399.
74. Liu, H.; Savaraj, N.; Priebe, W.; Lampidis, T.J. Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: A strategy for solid tumor therapy (Model C). Biochem. Pharmacol., 2002, 64, 1745-1751.
75. Maher, J.C.; Krishan, A.; Lampidis, T.J. Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-D-glucose in tumor cells treated under hypoxic vs aerobic conditions. Cancer Chemother. Pharmacol., 2004, 53, 116-122.
76. Mohanti, B.K.; Rath, G.K.; Anantha, N.; Kannan, V.; Das, B.S.; Chandramouli, B.A.; Banerjee, A.K.; Das, S.; Jena, A.; Ravichandran, R.; Sahi, U.P.; Kumar, R.; Kapoor, N.; Kalia, V.K.; Dwarakanath, B.S.; Jain, V. Improving cancer radiotherapy with 2-deoxy-D-glucose: Phase I/II clinical trials on human cerebral gliomas. Int. J. Radiat. Oncol. Biol. Phys., 1996, 35, 103-111.
77. Singh, D.; Banerji, A.K.; Dwarakanath, B.S.; Tripathi, R.P.; Gupta, J.P.; Mathew, T.L.; Ravindranath, T.; Jain, V. Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme. Strahlenther Onkol, 2005, 181, 507-514.
78. Chen, Z.; Lu, W.; Garcia-Prieto, C.; Huang, P. The Warburg effect and its cancer therapeutic implications. J. Bioenerg. Biomembr., 2007, 39, 267-274.
79. Brawer, M.K. Lonidamine: Basic science and rationale for treatment of prostatic proliferative disorders. Rev. Urol., 2005, 7 Suppl 7, S21-S26.
80. Di Cosimo, S.; Ferretti, G.; Papaldo, P.; Carlini, P.; Fabi, A.; Cognetti, F. Lonidamine: Efficacy and safety in clinical trials for the treatment of solid tumors. Drugs Today (Barc), 2003, 39, 157-174.
81. Amadori, D.; Frassineti, G.L.; De Matteis, A.; Mustacchi, G.; Santoro, A.; Cariello, S.; Ferrari, M.; Nascimben, O.; Nanni, O.; Lombardi, A.; Scarpi, E.; Zoli, W. Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients: Results from a multicenter prospective randomized trial. Breast Cancer Res. Treat., 1998, 49, 209-217.
82. De Lena, M.; Lorusso, V.; Latorre, A.; Fanizza, G.; Gargano, G.; Caporusso, L.; Guida, M.; Catino, A.; Crucitta, E.; Sambiasi, D.; Mazzei, A. Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study. Eur. J. Cancer, 2001, 37, 364-368.
83. Oudard, S.; Carpentier, A.; Banu, E.; Fauchon, F.; Celerier, D.; Poupon, M.F.; Dutrillaux, B.; Andrieu, J.M.; Delattre, J.Y. Phase II study of lonidamine and diazepam in the treatment of recurrent glioblastoma multiforme. J. Neurooncol., 2003, 63, 81-86.
84. Robey, R.B.; Hong, R.; Zhong, L.; Feng, L.; Zhang, H. Effects of the Anti-Tumor Agent 3-Bromopyruvate (3BrPA) on Glycolytic Energy Metabolism. FASEB J., 2007, 21, 890-896.
85. Chang, J.M.; Chung, J.W.; Jae, H.J.; Eh, H.; Son, K.R.; Lee, K.C.; Park, J.H. Local toxicity of hepatic arterial infusion of hexokinase II inhibitor, 3-bromopyruvate: In vivo investigation in normal rabbit model. Acad. Radiol., 2007, 14, 85-92.
86. Shin, S.W.; Han, H.; Choo, S.W.; Yoo, B.C.; Park, C.K.; Do, Y.S.; Lee, J.H.; Lee, D.H.; Choi, D.; Choo, I.W.; Kim, S.S.; Lee, J.Y. Hepatic intra-arterial injection of 3-bromopyruvate in rabbit VX2 tumor. Acta. Radiol., 2006, 47, 1036-1041.
87. Xu, R.H.; Pelicano, H.; Zhou, Y.; Carew, J.S.; Feng, L.; Bhalla, K.N.; Keating, M.J.; Huang, P. Inhibition of glycolysis in cancer cells: A novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res., 2005, 65, 613-621.
88. Devlin, T.M., Textbook of Biochemistry With Clinical Correlations, 6th Edition. John Wiley & Sons, Inc. Hoboken, NJ; 2006, p.581.
89. Rathmell, J.C.; Fox, C.J.; Plas, D.R.; Hammerman, P.S.; Cinalli, R.M.; Thompson, C.B. Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol. Cell Biol., 2003, 23, 7315-7328.
90. Bando, H.; Atsumi, T.; Nishio, T.; Niwa, H.; Mishima, S.; Shimizu, C.; Yoshioka, N.; Bucala, R.; Koike, T. Phosphorylation of the 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase/PFKFB3 family of glycolytic regulators in human cancer. Clin. Cancer Res., 2005, 11, 5784-5792.
91. Chesney, J. 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase and tumor cell glycolysis. Curr. Opin. Clin. Nutr. Metab. Care, 2006, 9, 535-539.
92. Clem, B.; Telang, S.; Clem, A.; Yalcin, A.; Meier, J.; Simmons, A.; Rasku, M. A.; Arumugam, S.; Dean, W.L.; Eaton, J.; Lane, A.; Trent, J.O.; Chesney, J. Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. Mol. Cancer Ther., 2008, 7, 110-120.
93. Riquelme, P.T.; Wernette-Hammond, M.E.; Kneer, N.M.; Lardy, H.A. Regulation of carbohydrate metabolism by 2,5-anhydro-D-mannitol. Proc. Natl. Acad. Sci. U.S.A., 1983, 80, 4301-4305
94. Bucala, R.J. US9823155.
95. Ismail, S.A.; Park, H.W. Structural analysis of human liver glyceraldehyde-3-phosphate dehydrogenase. Acta Crystallogr. D Biol. Crystallogr., 2005, 61, 1508-1513.
96. Lin, S.J.; Guarente, L. Nicotinamide adenine dinucleotide, a metabolic regulator of transcription, longevity and disease. Curr. Opin. Cell Biol., 2003, 15, 241-246.
97. Colell, A.; Ricci, J.E.; Tait, S.; Milasta, S.; Maurer, U.; Bouchier-Hayes, L.; Fitzgerald, P.; Guio-Carrion, A.; Waterhouse, N.J.; Li, C.W.; Mari, B.; Barbry, P.; Newmeyer, D.D.; Beere, H.M.; Green, D.R. GAPDH and autophagy preserve survival after apoptotic cytochrome c release in the absence of caspase activation. Cell, 2007, 129, 983-997.
98. Song, S.; Finkel, T. GAPDH and the search for alternative energy. Nat. Cell Biol., 2007, 9, 869-870.
99. Bressi, J.C.; Verlinde, C.L.; Aronov, A.M.; Shaw, M.L.; Shin, S.S.; Nguyen, L.N.; Suresh, S.; Buckner, F.S.; Van Voorhis, W.C.; Kuntz, I.D.; Hol, W.G.; Gelb, M.H. Adenosine analogues as selective inhibitors of glyceraldehyde-3-phosphate dehydrogenase of Trypanosomatidae via structure-based drug design. J. Med. Chem., 2001, 44, 2080-2093.
100. Lai1, J.C.K.; Bhardwaj, V.; Rizvi, N.; Chatterji, T.; Isaac, A.O.; Lai, M.B.; Johnson, T.; Leung, S.W.; Daniels, C.K.; Bhushan, A., Glycolytic enzyme inhibitors as novel anti-cancer drugs. The Northwest Regional Meeting, 2007, June 17-20, Boise, ID.
101. Paoluzzi, L.; Gonen, M.; Gardner, J.R.; Mastrella, J.; Yang, D.; Holmlund, J.; Sorensen, M.; Leopold, L.; Manova, K.; Marcucci, G.; Heaney, M.L.; O'Connor, O.A. Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma. Blood, 2008, 111, 5350-5361.
102. Mazurek, S.; Boschek, C.B.; Hugo, F.; Eigenbrodt, E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin. Cancer Biol., 2005, 15, 300-308.
103. Garcia-Alles, L.F.; Erni, B. Synthesis of phosphoenol pyruvate (PEP) analogues and evaluation as inhibitors of PEP-utilizing enzymes. Eur. J. Biochem., 2002, 269, 3226-3236.
104. Nowicki, M.W.; Tulloch, L.B.; Worralll, L.; McNae, I.W.; Hannaert, V.; Michels, P.A.; Fothergill-Gilmore, L.A.; Walkinshaw, M.D.; Turner, N.J. Design, synthesis and trypanocidal activity of lead compounds based on inhibitors of parasite glycolysis. Bioorg. Med. Chem., 2008, 16, 5050-5061.
105. http://www.thallion.com/en/index.php (The date of visit: March 8, 2009).
106. Choueiri, T.K. Factors associated with outcome in patients with advanced renal cell carcinoma in the era of antiangiogenic agents. Clin. Genitourin Cancer, 2008, 6, 15-20.
107. Kolev, Y.; Uetake, H.; Takagi, Y.; Sugihara, K. Lactate dehydrogenase-5 (LDH-5) expression in human gastric cancer: Association with hypoxia-inducible factor (HIF-1alpha) pathway, angiogenic factors production and poor prognosis. Ann. Surg. Oncol., 2008, 15, 2336-2344.
108. Fantin, V.R.; St-Pierre, J.; Leder, P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell, 2006, 9, 425-434.
109. Choi, S.R.; Pradhan, A.; Hammond, N.L.; Chittiboyina, A.G.; Tekwani, B.L.; Avery, M.A. Design, synthesis, and biological evaluation of Plasmodium falciparum lactate dehydrogenase inhibitors. J. Med. Chem., 2007, 50, 3841-3850.
110. Deck, L.M.; Royer, R.E.; Chamblee, B.B.; Hernandez, V.M.; Malone, R.R.; Torres, J.E.; Hunsaker, L.A.; Piper, R.C.; Makler, M.T.; Vander Jagt, D.L. Selective inhibitors of human lactate dehydrogenases and lactate dehydrogenase from the malarial parasite Plasmodium falciparum. J. Med. Chem., 1998, 41, 3879-3887.
111. Bonnet, S.; Archer, S.L.; Allalunis-Turner, J.; Haromy, A.; Beaulieu, C.; Thompson, R.; Lee, C.T.; Lopaschuk, G.D.; Puttagunta, L.; Bonnet, S.; Harry, G.; Hashimoto, K.; Porter, C.J.; Andrade, M.A.; Thebaud, B.; Michelakis, E.D. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell, 2007, 11, 37-51.
112. http://www.medicorcancer.com/DCAtherapy.html (The date of visit: March 8, 2009)
113. Pedersen, P.L. The cancer cell's "power plants" as promising therapeutic targets: An overview. J. Bioenerg. Biomembr., 2007, 39, 1-12.
114. Spencer, T.L.; Lehninger, A.L. L-lactate transport in Ehrlich ascites-tumour cells. Biochem. J., 1976, 154, 405-414.
115. Johnson, J.H.; Belt, J.A.; Dubinsky, W.P.; Zimniak, A.; Racker, E. Inhibition of lactate transport in Ehrlich ascites tumor cells and human erythrocytes by a synthetic anhydride of lactic acid. Biochemistry, 1980, 19, 3836-3840.
116. Mathupala, S.P.; Parajuli, P.; Sloan, A.E. Silencing of monocarboxylate transporters via small interfering ribonucleic acid inhibits glycolysis and induces cell death in malignant glioma: An in vitro study. Neurosurgery, 2004, 55, 1410-1419.
117. Fang, J.; Quinones, Q.J.; Holman, T.L.; Morowitz, M.J.; Wang, Q.; Zhao, H,; Sivo, F.; Maris, J.M.; Wahl, M.L. The H+-linked monocarboxylate transporter (MCT1/SLC16A1): A potential therapeutic target for high-risk neuroblastoma. Mol. Pharmacol., 2006, 70, 2108-2115.
118. Fais, S.; De Milito, A.; You, H.; Qin, W. Targeting vacuolar H+-ATPases as a new strategy against cancer. Cancer Res., 2007, 67, 10627-10630.
119. Zambell, K.L.; Fitch, M.D.; Fleming, S.E. Acetate and butyrate are the major substrates for de novo lipogenesis in rat colonic epithelial cells. J. Nutr., 2003, 133, 3509-3515.
120. Wakil, S.J. Fatty acid synthase, a proficient multifunctional enzyme. Biochemistry, 1989, 28, 4523-4530.
121. Swinnen, J.V.; Roskams, T.; Joniau, S.; Van Poppel, H.; Oyen, R.; Baert, L.; Heyns, W.; Verhoeven, G. Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int. J. Cancer, 2002, 98, 19-22.
122. Baron, A.; Migita, T.; Tang, D.; Loda, M. Fatty acid synthase: A metabolic oncogene in prostate cancer? J. Cell Biochem., 2004, 91, 47-53.
123. Liu, Y. Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis., 2006, 9, 230-234.
124. Kridel, S.J.; Lowther, W.T.; Pemble, C.W.T. Fatty acid synthase inhibitors: New directions for oncology. Expert Opin.. Investig. Drugs, 2007, 16, 1817-1829.
125. Funabashi, H.; Kawaguchi, A.; Tomoda, H.; Omura, S.; Okuda, S.; Iwasaki, S. Binding site of cerulenin in fatty acid synthetase. J. Biochem., 1989, 105, 751-755.
126. Pizer, E.S.; Jackisch, C.; Wood, F.D.; Pasternack, G.R.; Davidson, N.E.; Kuhajda, F.P. Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells. Cancer Res., 1996, 56, 2745-2747.
127. Pizer, E.S.; Wood, F.D.; Heine, H.S.; Romantsev, F.E.; Pasternack, G.R.; Kuhajda, F.P. Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. Cancer Res., 1996, 56, 1189-1193.
128. Gabrielson, E.W.; Pinn, M.L.; Testa, J.R.; Kuhajda, F.P. Increased fatty acid synthase is a therapeutic target in mesothelioma. Clin. Cancer Res., 2001, 7, 153-157.
129. Wang, H.Q.; Altomare, D.A.; Skele, K.L.; Poulikakos, P.I.; Kuhajda, F.P.; Di Cristofano, A.; Testa, J.R. Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene, 2005, 24, 3574-3582
130. Zhou, W.; Han, W.F.; Landree, L.E.; Thupari, J.N.; Pinn, M.L.; Bililign, T.; Kim, E.K.; Vadlamudi, A.; Medghalchi, S.M.; El Meskini, R.; Ronnett, G.V.; Townsend, C.A.; Kuhajda, F.P. Fatty acid synthase inhibition activates AMP-activated protein kinase in SKOV3 human ovarian cancer cells. Cancer Res., 2007, 67, 2964-2971.
131. Alli, P.M.; Pinn, M.L.; Jaffee, E.M.; McFadden, J.M.; Kuhajda, F.P. Fatty acid synthase inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice. Oncogene, 2005, 24, 39-46
132. Price, A.C.; Choi, K.H.; Heath, R.J.; Li, Z.; White, S.W.; Rock, C.O. Inhibition of beta-ketoacyl-acyl carrier protein synthases by thiolactomycin and cerulenin. Structure and mechanism. J. Biol. Chem., 2001, 276, 6551-6559.
133. Pizer, E.S.; Thupari, J.; Han, W.F.; Pinn, M.L.; Chrest, F.J.; Frehywot, G.L.; Townsend, C.A.; Kuhajda, F.P. Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res., 2000, 60, 213.
134. Kridel, S.J.; Axelrod, F.; Rozenkrantz, N.; Smith, J.W. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res., 2004, 64, 2070-2075.
135. Knowles, L.M.; Axelrod, F.; Browne, C.D.; Smith, J.W. A fatty acid synthase blockade induces tumor cell-cycle arrest by down-regulating Skp2. J. Biol. Chem., 2004, 279, 30540-30545.
136. Zhou, W.; Simpson, P.J.; McFadden, J.M.; Townsend, C.A.; Medghalchi, S.M.; Vadlamudi, A.; Pinn, M.L.; Ronnett, G.V.; Kuhajda, F.P. Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells. Cancer Res., 2003, 63, 7330-7337.
137. Ma, G.; Zancanella, M.; Oyola, Y.; Richardson, R.D.; Smith, J.W.; Romo, D. Total synthesis and comparative analysis of orlistat, valilactone, and a transposed orlistat derivative: inhibitors of fatty acid synthase. Org. Lett., 2006, 8, 4497-4500.
138. Purohit, V.C.; Richardson, R.D.; Smith, J.W.; Romo, D. Practical, catalytic, asymmetric synthesis of β-lactones via a sequential ketene dimerization/hydrogenation process: Inhibitors of the thioesterase domain of fatty acid synthase. J. Org. Chem., 2006, 71, 4549-4558.
139. Li, B.H.; Ma, X.F.; Wang, Y.; Tian, W.X. Structure-activity relationship of polyphenols that inhibit fatty acid synthase. J. Biochem. (Tokyo), 2005, 138, 679-685.
140. Wang, X.; Tian, W. Green tea epigallocatechin gallate: A natural inhibitor of fatty-acid synthase. Biochem. Biophys. Res. Commun., 2001, 288, 1200-1206.
141. Brusselmans, K.; De Schrijver, E.; Heyns, W.; Verhoeven, G.; Swinnen, J.V. Epigallocatechin-3-gallate is a potent natural inhibitor of fatty acid synthase in intact cells and selectively induces apoptosis in prostate cancer cells. Int. J. Cancer, 2003, 106, 856-862.
142. Brusselmans, K.; Vrolix, R.; Verhoeven, G.; Swinnen, J.V. Induction of cancer cell apoptosis by flavonoids is associated with their ability to inhibit fatty acid synthase activity. J. Biol. Chem., 2005, 280, 5636-5645.
143. Li, B.H.; Tian, W.X. Inhibitory effects of flavonoids on animal fatty acid synthase. J. Biochem., 2004, 135, 85-91.
144. Szutowicz, A.; Kwiatkowski, J.; Angielski, S. Lipogenetic and glycolytic enzyme activities in carcinoma and nonmalignant diseases of the human breast. Br. J. Cancer, 1979, 39, 681-687.
145. Turyn, J.; Schlichtholz, B.; Dettlaff-Pokora, A.; Presler, M.; Goyke, E.; Matuszewski, M.; Kmiec, Z.; Krajka, K.; Swierczynski, J. Increased activity of glycerol 3-phosphate dehydrogenase and other lipogenic enzymes in human bladder cancer. Horm. Metab. Res., 2003, 35, 565-569.
146. Pearce, N.J.; Yates, J.W.; Berkhout, T.A.; Jackson, B.; Tew, D.; Boyd, H.; Camilleri, P.; Sweeney, P.; Gribble, A.D.; Shaw, A.; Groot, P.H. The role of ATP citrate-lyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076. Biochem. J., 1998, 334, 113-119.
147. Hatzivassiliou, G.; Zhao, F.; Bauer, D.E.; Andreadis, C.; Shaw, A.N.; Dhanak, D.; Hingorani, S.R.; Tuveson, D.A.; Thompson, C.B. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell, 2005, 8, 311-321.
148. Migita, T.; Narita, T.; Nomura, K.; Miyagi, E.; Inazuka, F.; Matsuura, M.; Ushijima, M.; Mashima, T.; Seimiya, H.; Satoh, Y.; Okumura, S.; Nakagawa, K.; Ishikawa, Y. ATP citrate lyase: Activation and therapeutic implications in non-small cell lung cancer. Cancer Res., 2008, 68, 8547-8554.
149. Carretero, J.; Medina, P.P.; Blanco, R.; Smit, L.; Tang, M.; Roncador, G.; Maestre, L.; Conde, E.; Lopez-Rios, F.; Clevers, H.C.; Sanchez-Cespedes, M. Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer. Oncogene, 2007, 26, 1616-1625.
150. Moreau, K.; Dizin, E.; Ray, H.; Luquain, C.; Lefai, E.; Foufelle, F.; Billaud, M.; Lenoir, G. M.; Venezia, N.D. BRCA1 affects lipid synthesis through its interaction with acetyl-CoA carboxylase. J. Biol. Chem., 2006, 281, 3172-3181.
151. Brusselmans, K.; De Schrijver, E.; Verhoeven, G.; Swinnen, J.V. RNA interference-mediated silencing of the acetyl-CoA-carboxylase-alpha gene induces growth inhibition and apoptosis of prostate cancer cells. Cancer Res., 2005, 65, 6719-6725.
152. Chajes, V.; Cambot, M.; Moreau, K.; Lenoir, G.M.; Joulin, V. Acetyl-CoA carboxylase alpha is essential to breast cancer cell survival. Cancer Res., 2006, 66, 5287-5294.
153. Gerth, K.; Bedorf, N.; Irschik, H.; Hofle, G.; Reichenbach, H., J. Antibiot. (Tokyo), 1994, 47, 23.
154. Shen, Y.; Volrath, S.L.; Weatherly, S.C.; Elich, T.D.; Tong, L. A mechanism for the potent inhibition of eukaryotic acetyl-coenzyme A carboxylase by soraphen A, a macrocyclic polyketide natural product. Mol. Cell., 2004, 16, 881-891.
155. Beckers, A.; Organe, S.; Timmermans, L.; Scheys, K.; Peeters, A.; Brusselmans, K.; Verhoeven, G.; Swinnen, J.V. Chemical inhibition of acetyl-CoA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells. Cancer Res., 2007, 67, 8180-8187.
156. Aoyama, C.; Liao, H.; Ishidate, K. Structure and function of choline kinase isoforms in mammalian cells. Prog. Lipid Res., 2004, 43, 266-281.
157. Ramirez de Molina, A.; Gutierrez, R.; Ramos, M.A.; Silva, J.M.; Silva, J.; Bonilla, F.; Sanchez, J.J.; Lacal, J.C. Increased choline kinase activity in human breast carcinomas: Clinical evidence for a potential novel antitumor strategy. Oncogene, 2002, 21, 4317-4322.
158. Janardhan, S.; Srivani, P.; Sastry, G.N. Choline kinase: An important target for cancer. Curr. Med. Chem., 2006, 13, 1169-1186.
159. Al-Saffar, N.M.; Troy, H.; Ramirez de Molina, A.; Jackson, L.E.; Madhu, B.; Griffiths, J.R.; Leach, M.O.; Workman, P.; Lacal, J.C.; Judson, I.R.; Chung, Y.L. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models. Cancer Res., 2006, 66, 427- 34.
160. Hernandez-Alcoceba, R.; Fernandez, F.; Lacal, J.C. In vivo antitumor activity of choline kinase inhibitors: A novel target for anticancer drug discovery. Cancer Res., 1999, 59, 3112-3118.
161. Kaelin, W.G., Jr.; Ratcliffe, P.J. Oxygen sensing by metazoans: The central role of the HIF hydroxylase pathway. Mol. Cell, 2008, 30, 393-402.
162. Carnero, A.; Blanco-Aparicio, C.; Renner, O.; Link, W.; Leal, J.F. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr. Cancer Drug Targets, 2008, 8, 187-198.
163. Strimpakos, A.S.; Karapanagiotou, E.M.; Saif, W.M.; Syrigos, K.N. Cancer Treat. Rev., 2008. (Online version)
164. Vivanco, I.; Sawyers, C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer, 2002, 2, 489-501.
165. Stambolic, V.; Suzuki, A.; de la Pompa, J.L.; Brothers, G.M.; Mirtsos, C.; Sasaki, T.; Ruland, J.; Penninger, J.M.; Siderovski, D.P.; Mak, T.W. Negative regulation of PKB/Akt-dependent cell survival by the tumor
166. Wu, X.; Senechal, K.; Neshat, M.S.; Whang, Y.E.; Sawyers, C.L. The PTEN/ MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc. Natl. Acad. Sci. USA, 1998, 95, 15587-15591.
167. Larue, L.; Bellacosa, A. Epithelial-mesenchymal transition in development and cancer: Role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene, 2005, 24, 7443-7454.
168. Hatzivassiliou, G.; Andreadis, C.; Thompson, C.B. Akt-directed metabolic alterations in cancer. Drug Discov Today Dis Mech., 2005, 2, 255-262.
169. Faivre, S.; Kroemer, G.; Raymond, E. Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov., 2006, 5, 671-688.
170. Schmelzle, T.; Hall, M.N. TOR, a central controller of cell growth. Cell, 2000, 103, 253-262.
171. Shin, I.; Edl, J.; Biswas, S.; Lin, P.C.; Mernaugh, R.; Arteaga, C.L. Proapoptotic activity of cell-permeable anti-Akt single-chain antibodies. Cancer Res., 2005, 65, 2815-2824.
172. Li, Q.; Zhu, G.D. Targeting serine/threonine protein kinase B/Akt and cell-cycle checkpoint kinases for treating cancer. Curr. Top. Med. Chem., 2002, 2, 939-971.
173. Lippa, B. Inhibitors of Akt Activity. Expert Opin. Ther. Patents, 2007, 17, 577-581.
174. Breitenlechner, C.B.; Wegge, T.; Berillon, L.; Graul, K.; Marzenell, K.; Friebe, W.G.; Thomas, U.; Schumacher, R.; Huber, R.; Engh, R.A.; Masjost, B. Structure-based optimization of novel azepane derivatives as PKB inhibitors. J. Med. Chem., 2004, 47, 1375-1390.
175. Li, Q.; Li, T.; Zhu, G.D.; Gong, J.; Claibone, A.; Dalton, C.; Luo, Y.; Johnson, E.F.; Shi, Y.; Liu, X.; Klinghofer, V.; Bauch, J.L.; Marsh, K.C.; Bouska, J.J.; Arries, S.; De Jong, R.; Oltersdorf, T.; Stoll, V.S.; Jakob, C.G.; Rosenberg, S.H.; Giranda, V.L. Discovery of trans-3,4′-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation. Bioorg. Med. Chem. Lett., 2006, 16, 1679-1685.
176. Li, Q.; Woods, K.W.; Thomas, S.; Zhu, G.D.; Packard, G.; Fisher, J.; Li, T.; Gong, J.; Dinges, J.; Song, X.; Abrams, J.; Luo, Y.; Johnson, E.F.; Shi, Y.; Liu, X.; Klinghofer, V.; Des Jong, R.; Oltersdorf, T.; Stoll, V.S.; Jakob, C.G.; Rosenberg, S.H.; Giranda, V.L. Synthesis and structure-activity relationship of 3,4′-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer. Bioorg. Med. Chem. Lett., 2006, 16, 2000-2007.
177. Woods, K.W.; Fischer, J.P.; Claiborne, A.; Li, T.; Thomas, S.A.; Zhu, G.D.; Diebold, R.B.; Liu, X.; Shi, Y.; Klinghofer, V.; Han, E.K.; Guan, R.; Magnone, S.R.; Johnson, E.F.; Bouska, J.J.; Olson, A.M.; de Jong, R.; Oltersdorf, T.; Luo, Y.; Rosenberg, S.H.; Giranda, V.L.; Li, Q. Synthesis and SAR of indazole-pyridine based protein kinase B/Akt inhibitors. Bioorg. Med. Chem., 2006, 14, 6832-6846.
178. Zhu, G.D.; Gong, J.; Claiborne, A.; Woods, K.W.; Gandhi, V.B.; Thomas, S.; Luo, Y.; Liu, X.; Shi, Y.; Guan, R.; Magnone, S.R.; Klinghofer, V.; Johnson, E.F.; Bouska, J.; Shoemaker, A.; Oleksijew, A.; Stoll, V.S.; De Jong, R.; Oltersdorf, T.; Li, Q.; Rosenberg, S.H.; Giranda, V.L. Isoquinoline-pyridine-based protein kinase B/Akt antagonists: SAR and in vivo antitumor activity Bioorg. Med. Chem. Lett., 2006, 16, 3150-3155
179. Shi, Y.; Liu, X.; Han, E.K.; Guan, R.; Shoemaker, A.R.; Oleksijew, A.; Woods, K.W.; Fisher, J.P.; Klinghofer, V.; Lasko, L.; McGonigal, T.; Li, Q.; Rosenberg, S.H.; Giranda, V.L.; Luo, Y. Optimal classes of chemotherapeutic agents sensitized by specific small-molecule inhibitors of akt in vitro and in vivo. Neoplasia, 2005, 7, 992-1000.
180. Lin, X.; Murray, J.M.; Rico, A.C.; Wang, M.X.; Chu, D.T.; Zhou, Y.; Del Rosario, M.; Kaufman, S.; Ma, S.; Fang, E.; Crawford, K.; Jefferson, A.B. Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for AKT: Synthesis and SAR studies. Bioorg. Med. Chem. Lett., 2006, 16, 4163-4168.
181. Ko, J.H.; Yeon, S.W.; Ryu, J.S.; Kim, T.Y.; Song, E.H.; You, H.J.; Park, R.E.; Ryu, C.K. Synthesis and biological evaluation of 5-arylamino-6-chloro-1H-indazole-4,7-diones as inhibitors of protein kinase B/Akt. Bioorg. Med. Chem. Lett., 2006, 16, 6001-6005.
182. Gills, J.J.; Dennis, P.A. The development of phosphatidylinositol ether lipid analogues as inhibitors of the serine/threonine kinase, Akt. Expert Opin. Investig. Drugs, 2004, 13, 787-797.
183. Powis, G.; Aksoy, I.A.; Melder, D.C.; Aksoy, S.; Eichinger, H.; Fauq, A.H.; Kozikowski, A.P. D-3-deoxy-3-substituted myoinositol analogues as inhibitors of cell growth. Cancer Chemother. Pharmacol., 1991, 29, 95-104.
184. Kozikowski, A.P.; Kiddle, J.J.; Frew, T.; Berggren, M.; Powis, G. Synthesis and biology of 1D-3-deoxyphosphatidylinositol: A putative antimetabolite of phosphatidylinositol-3-phosphate and an inhibitor of cancer cell colony formation. J. Med. Chem., 1995, 38, 1053-1056.
185. Qiao, L.; Nan, F.; Kunkel, M.; Gallegos, A.; Powis, G.; Kozikowski, A.P. 3-Deoxy-D-myo-inositol 1-phosphate, 1-phosphonate, and ether lipid analogues as inhibitors of phosphatidylinositol-3-kinase signaling and cancer cell growth. J. Med. Chem., 1998, 41, 3303-3036.
186. Castillo, S.S.; Brognard, J.; Petukhov, P.A.; Zhang, C.; Tsurutani, J.; Granville, C.A.; Li, M.; Jung, M.; West, K.A.; Gills, J.G.; Kozikowski, A.P.; Dennis, P.A. Preferential inhibition of Akt and killing of Akt-dependent cancer cells by rationally designed phosphatidylinositol ether lipid analogues. Cancer Res., 2004, 64, 2782-2792.
187. Yang, L.; Dan, H.C.; Sun, M.; Liu, Q.; Sun, X.M.; Feldman, R.I.; Hamilton, A.D.; Polokoff, M.; Nicosia, S.V.; Herlyn, M.; Sebti, S.M.; Cheng, J.Q. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res., 2004, 64, 4394-4399.
188. Feun, L.G.; Blessing, J.A.; Barrett, R.J.; Hanjani, P. A phase II trial of tricyclic nucleoside phosphate in patients with advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Study. Am. J. Clin. Oncol., 1993, 16, 506-508.
189. Feun, L.G.; Savaraj, N.; Bodey, G.P.; Lu, K.; Yap, B.S.; Ajani, J.A.; Burgess, M.A.; Benjamin, R.S.; McKelvey, E.; Krakoff, I. Phase I study of tricyclic nucleoside phosphate using a five-day continuous infusion schedule. Cancer Res., 1984, 44, 3608-3612.
190. Jong, L.; Chao, W.R.; Amin, K.; Laderoute, K.; Orduna, J.; Sato, B.; Rice, G. SR13668: A novel indole derived inhibitor of phospho-Akt potently suppresses tumor growth in various murine xenograft models. AACR Meeting Abstracts 2004, 2004, 849-850.
191. Barnett, S.F.; Defeo-Jones, D.; Fu, S.; Hancock, P.J.; Haskell, K.M.; Jones, R.E.; Kahana, J.A.; Kral, A.M.; Leander, K.; Lee, L.L.; Malinowski, J.; McAvoy, E.M.; Nahas, D.D.; Robinson, R.G.; Huber, H.E. Identification and characterization of pleckstrinhomology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem. J., 2005, 385, 399-408.
192. Lindsley, C.W.; Zhao, Z.; Leister, W.H.; Robinson, R.G.; Barnett, S.F.; Defeo-Jones, D.; Jones, R.E.; Hartman, G.D.; Huff, J.R.; Huber, H.E.; Duggan, M.E. Allosteric Akt (PKB) inhibitors: Discovery and SAR of isozyme selective inhibitors. Bioorg. Med. Chem. Lett., 2005, 15, 761-764.
193. Lindsley, C.W.; Bogusky, M.J.; Leister, W.H.; McClain, R.T.; Robinson, R.; Barnett, S.F.; Defeo-Jones, D.; III Ross, C.W.; Hartman, G.D. Synthesis and biological evaluation of unnatural canthine alkaloids. Tetrahedron Lett., 2005, 46, 2779-2782.
194. Cho, D.; Signoretti, S.; Regan, M.; Mier, J.W.; Atkins, M.B., The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin. Cancer Res., 2007, 13, 758s-763s.
195. Sehgal, S.N.; Baker, H.; Vezina, C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J. Antibiot (Tokyo), 1975, 28, 727-732.
196. Humar, R.; Kiefer, F.N.; Berns, H.; Resink, T.J.; Battegay, E.J. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J., 2002, 16, 771-780.
197. Gibbons, J.J.; Discafani, C.; Peterson, R.; Hernandez, R.; Skotnicki, J.; Frost, P. The effect of CCI-779, a novel macrolide antitumor agent, on the growth of human tumor cells in vitro and in nude mouse xenograft in vivo. Proc. Am. Assoc. Cancer Res., 2000, 40, 301.
198. Cho, D.; Signoretti, S.; Regan, M.; Mier, J. W.; Atkins, M. B. The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin. Cancer Res., 2007, 13, 758s-763s.
199. Klupp, J.; Langrehr, M.L.; Junge, G.; Neuhaus, P. Inhibitors of mammalian target of rapamycin. Drugs Fut., 2001, 26, 1179-1189.
200. Mita, M.; Sankhala, K.; Abdel-Karim, I.; Mita, A.; Giles, F. Deforolimus (AP23573) a novel mTOR inhibitor in clinical development. Expert Opin. Investig. Drugs, 2008, 17, 1947-1954.
201. Ryan, H.E.; Lo, J.; Johnson, R.S. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J., 1998, 17, 3005-3015.
202. Greijer, A.E.; van der Groep, P.; Kemming, D.; Shvarts, A.; Semenza, G.L.; Meijer, G.A.; van de Wiel, M.A.; Belien, J.A.; van Diest, P.J.; van der Wall, E. Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1). J. Pathol., 2005, 206, 291-304.
203. Kim, J.W.; Tchernyshyov, I.; Semenza, G.L.; Dang, C.V., HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metab., 2006, 3, 177-185.
204. Sang, N.; Stiehl, D.P.; Bohensky, J.; Leshchinsky, I.; Srinivas, V.; Caro, J. MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300. J. Biol. Chem., 2003, 278, 14013-14019.
205. Welsh, S.; Williams, R.; Kirkpatrick, L.; Paine-Murrieta, G.; Powis, G. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol. Cancer Ther., 2004, 3, 233-244.
206. Yeo, E.J.; Chun, Y.S.; Cho, Y.S.; Kim, J.; Lee, J.C.; Kim, M.S.; Park, J.W. YC-1: A potential anticancer drug targeting hypoxia-inducible factor 1. J. Natl. Cancer Inst., 2003, 95, 516-525.
207. Kong, D.; Park, E.J.; Stephen, A.G.; Calvani, M.; Cardellina, J.H.; Monks, A.; Fisher, R.J.; Shoemaker, R.H.; Melillo, G. Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res., 2005, 65, 9047-9055.
208. Newcomb, E.W.; Ali, M.A.; Schnee, T.; Lan, L.; Lukyanov, Y.; Fowkes, M.; Miller, D.C.; Zagzag, D. Flavopiridol downregulates hypoxia-mediated hypoxia-inducible factor-1alpha expression in human glioma cells by a proteasome-independent pathway: Implications for in vivo therapy. Neuro. Oncol., 2005, 7, 225-235.
209. Chang, H.; Shyu, K.G.; Lee, C.C.; Tsai, S.C.; Wang, B.W.; Hsien Lee, Y.; Lin, S. GL331 inhibits HIF-1alpha expression in a lung cancer model. Biochem. Biophys. Res. Commun., 2003, 302, 95-100.
210. Laughner, E.; Taghavi, P.; Chiles, K.; Mahon, P.C.; Semenza, G.L. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell Biol., 2001, 21, 3995-4004.
211. Mayerhofer, M.; Valent, P.; Sperr. W.R.; Griffin, J.D.; Sillaber, C. BCR/ ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood, 2002, 100, 3767-3775.
212. Koukourakis, M.I.; Simopoulos, C.; Polychronidis, A.; Perente, S.; Botaitis, S.; Giatromanolaki, A.; Sivridis, E. The effect of trastuzumab/ docatexel combination on breast cancer angiogenesis: Dichotomus effect predictable by the HIFI alpha/VEGF pre-treatment status?. Anticancer Res., 2003, 23, 1673-1680.
213. Hirota, K.; Semenza, G.L. Rac1 activity is required for the activation of hypoxia-inducible factor 1. J. Biol. Chem., 2001, 276, 21166-21172.
214. Richard, D.E.; Berra, E.; Gothie, E.; Roux, D.; Pouyssegur, J. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. J. Biol. Chem., 1999, 274, 32631-32637.
215. Hardie, D.G.; Scott, J.W.; Pan, D.A.; Hudson, E.R. Management of cellular energy by the AMP-activated protein kinase system. FEBS Lett., 2003, 546, 113-120.
216. Bolster, D.R.; Crozier, S.J.; Kimball, S.R.; Jefferson, L.S. AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling. J. Biol. Chem., 2002, 277, 23977-23980.
217. Motoshima, H.; Goldstein, B.J.; Igata, M.; Araki, E. AMPK and cell proliferation - AMPK as a therapeutic target for atherosclerosis and cancer. J. Physiol., 2006, 574, 63-71.
218. Evans, J.M.; Donnelly, L.A.; Emslie-Smith, A.M.; Alessi, D.R.; Morris, A.D. Metformin and reduced risk of cancer in diabetic patients. BMJ, 2005, 330, 1304-1305.
219. Bowker, S.L.; Majumdar, S.R.; Veugelers, P.; Johnson, J.A. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin: Response to Farooki and Schneider. Diabetes Care, 2006, 29, 1990-1991.
220. Zakikhani, M.; Dowling, R.; Fantus, I.G.; Sonenberg, N.; Pollak, M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res., 2006, 66, 10269-10273.
221. Xiang, X.; Saha, A.K.; Wen, R.; Ruderman, N.B.; Luo, Z. AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem. Biophys. Res. Commun., 2004, 321, 161-167.